Table 2.
Treatment Outcomes of Patients with Gastric MALT Lymphoma according to Helicobacter pylori Infection Status
| Total (n=345) | H. pylori-positive (n=317) | H. pylori-negative (n=28) | p-value | |
|---|---|---|---|---|
| CR after HPE | 284 (82.3) | 268 (84.5) | 16 (57.1) | 0.001 |
| CR* | 301 (87.2) | 280 (88.3) | 21 (75.0) | 0.068 |
| Time to CR, mo | 9.9 (7.2–15.6) | 9.8 (7.1–15.6) | 11.5 (10.0–22.3) | 0.106 |
| Relapse | 32 (10.6) | 30 (10.7) | 2 (9.5) | 1.000 |
| Time to relapse, mo | 11.5 (6.2–16.8) | 11.5 (6.3–21.0) | 8.1(5.7–10.6) | 0.370 |
| CR after relapse | 24/29† (82.8) | 22/27† (81.5) | 2 (100.0) | NA |
| Treatment failure | 49/342† (14.3) | 42/314† (13.4) | 7 (25.0) | 0.097 |
Data are presented as number (%) or median (range).
MALT, mucosa-associated lymphoid tissue; CR, complete remission; HPE, H. pylori eradication therapy; NA, not assessed.
*
Overall CR rate after additional treatment;
†
Two patients have not yet undergone two of the follow-up endoscopies, and one patient was lost to follow-up.